Ibrutinib 420 mg
| Product Overview | |
| Generic Name | Ibrutinib 420 mg |
| Brand Name(s) | IMBRUVICA® |
| Form | Capsules, film-coated tablets & oral suspension |
| Strength | 420 mg |
| Therapeutic Class | Bruton’s tyrosine kinase (BTK) inhibitor |
| ATC Code | L01EL01 |
| Manufacturing & Regulatory | |
| Manufacturer | Pharmacyclics LLC (AbbVie), Janssen |
| Country | USA, EU, India |
| GMP Compliance | WHO-GMP |
| COFEPRIS | 010.000.7108.00 |
| Free Sale Certificate | Available per batch upon request |
| Logistics & Export | |
| MOQ | 5 units |
| Shelf Life | 36 months |
| Storage | Store below 30°C Protect from moisture and light |
| Incoterms | EXW/FOB/CIF negotiable |
| Lead Time | 7 - 10 Business Days |
| Documentation | |
| Certificate of Analysis (COA) | Supplied per batch upon request |
Description
Ibrutinib is a BTK inhibitor indicated across multiple B-cell malignancies
Brand Pricing: 140mg 30 Tab U$D 5,295.00
